AIDS vaccine trial exceeds expectations

Sep 23, 2005

An experimental AIDS vaccine of Merck & Co. has exceeded expectations and led to a double enrollment in the trial to 3,000, researchers said.

The trial, conducted in healthy volunteers to determine their immune response to the vaccine, might indicate whether the immune reactions could prevent or control AIDS, reported the Wall Street Journal Friday.

The vaccine, called MRKAd5, uses an adenovirus -- a common-cold virus -- as a missile armed with man-made copies of three AIDS virus genes, has resulted in a stronger-than-expected immune response.

MRKAd5 has boosted such killer T-cells, which seek and destroy human cells infected by HIV by 50-fold to 100-fold -- an immune reaction comparable with successful vaccines for diseases like smallpox or measles, according to Lawrence Corey, principal investigator of the HIV Vaccine Trials Network in Seattle.

However, the vaccine doesn't elicit antibodies, another key element of immune protection.

Copyright 2005 by United Press International

Explore further: Crude conspiracy theories could be right, study shows

add to favorites email to friend print save as pdf

Related Stories

Davos elites warned about catastrophic cyberattacks

1 hour ago

Attacks on power plants, telecommunications and financial systems, even turning all of Los Angeles' traffic lights green: Davos elites were warned Saturday of the terrifying possibilities of modern cyber terrorism.

Recommended for you

Retreat of multiculturalism 'is a myth'

16 hours ago

Perceptions of a decline in multiculturalism as a means of integrating ethnic minorities are unfounded, research led at the University of Strathclyde has found.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.